The Robinson campus handled administration of Bayer’s operations in North America and some product development.
The closure is a result of a companywide consolidation plan, which includes eliminating 12,000 jobs worldwide. The decision to consolidate comes after the drugmaker’s $63 billion acquisition of seed maker Monsanto last year.
“In the U.S., we are beginning to implement this by consolidating administrative functions,” Bayer told The Post-Gazette.
The decision will affect 569 company employees and 96 contractors. Bayer has contacted affected employees.
The closure will take place over two years.
More articles on pharmacy:
House panel launches drug-pricing probe of 12 pharma companies
Key thoughts on controlling pharmacy spend for hospitals
Dispensary of Hope’s pharmaceutical director Dr. Hillary Blackburn on what makes a dynamic, influential leader
